The +869T/C polymorphism in the transforming growth factor-β1 gene is associated with the severity and intractability of autoimmune thyroid disease

H. Yamada, M. Watanabe, T. Nanba, T. Akamizu, Y. Iwatani

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

The severity of Hashimoto's disease (HD) and the intractability of Graves' disease (GD) vary among patients. To clarify whether the +869T/C polymorphism in the transforming growth factor-β1 (TGF-β1) gene, which is associated with TGF-β1 expression, is involved in the intractability of GD and severity of HD, we genotyped the TGF-β1 +869T/C polymorphism by polymerase chain reaction-restriction fragment length polymorphism method in genomic DNA samples from 33 patients with HD who developed hypothyroidism before they were 50 years old (severe HD) and 30 untreated, euthyroid patients with HD who were older than 50 years (mild HD). We also examined 48 euthyroid patients with GD who had been under treatment and were still positive for anti-thyrotropin receptor antibodies (intractable GD), 20 euthyroid patients with GD in remission and 45 healthy controls. The frequency of the T allele and the TT genotype were higher in patients with severe HD than in those with in mild HD. In contrast, the frequency of the CC genotype was higher in patients with intractable GD than in patients with GD in remission. In conclusion, the +869T/C polymorphism in the TGF-β1 gene is associated with the severity and intractability of autoimmune thyroid disease.

Original languageEnglish
Pages (from-to)379-382
Number of pages4
JournalClinical and Experimental Immunology
Volume151
Issue number3
DOIs
Publication statusPublished - 01-03-2008
Externally publishedYes

    Fingerprint

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Immunology

Cite this